
Dirk Bier

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2027104/publications.pdf Version: 2024-02-01



DIDK RIFD

#	Article	IF	CITATIONS
1	Delivery of the Radionuclide 1311 Using Cationic Fusogenic Liposomes as Nanocarriers. International Journal of Molecular Sciences, 2021, 22, 457.	4.1	7
2	Species Differences in Microsomal Metabolism of Xanthine-Derived A1 Adenosine Receptor Ligands. Pharmaceuticals, 2021, 14, 277.	3.8	1
3	Design, synthesis and biological evaluation of Tozadenant analogues as adenosine A2A receptor ligands. European Journal of Medicinal Chemistry, 2021, 214, 113214.	5.5	9
4	[¹⁸ F]ALX5406: A Brain-Penetrating Prodrug for GlyT1-Specific PET Imaging. ACS Chemical Neuroscience, 2021, 12, 3335-3346.	3.5	8
5	Hypericin and its radio iodinated derivatives – A novel combined approach for the treatment of pediatric alveolar rhabdomyosarcoma cells in vitro. Photodiagnosis and Photodynamic Therapy, 2020, 29, 101588.	2.6	12
6	Influence of binding affinity and blood plasma level on cerebral pharmacokinetics and PET imaging characteristics of two novel xanthine PET radioligands for the A1 adenosine receptor. Nuclear Medicine and Biology, 2020, 82-83, 1-8.	0.6	1
7	Preparation of 5-[131I]iodotubercidin for the detection of adenosine kinase. Journal of Radioanalytical and Nuclear Chemistry, 2020, 326, 1691-1697.	1.5	0
8	Development and Evaluation of a Versatile Receptor-Ligand Binding Assay Using Cell Membrane Preparations Embedded in an Agarose Gel Matrix and Evaluation with the Human Adenosine A1Receptor. Assay and Drug Development Technologies, 2020, 18, 328-340.	1.2	1
9	Relevance of In Vitro Metabolism Models to PET Radiotracer Development: Prediction of In Vivo Clearance in Rats from Microsomal Stability Data. Pharmaceuticals, 2019, 12, 57.	3.8	10
10	Influence of incubation conditions on microsomal metabolism of xanthine-derived A1 adenosine receptor ligands. Journal of Pharmacological and Toxicological Methods, 2019, 95, 16-26.	0.7	6
11	Synthesis and Pharmacological Evaluation of Identified and Putative Metabolites of the A ₁ Adenosine Receptor Antagonist 8 yclopentylâ€3â€{3â€fluoropropyl)â€1â€propylxanthine (CPFPX). ChemMed 2017, 12, 770-784.	Ctaem,	3
12	Efficient synthesis of [¹⁸ F]FPyME: A new approach for the preparation of maleimideâ€containing prosthetic groups for the conjugation with thiols. Journal of Labelled Compounds and Radiopharmaceuticals, 2017, 60, 87-92.	1.0	6
13	New potent A1 adenosine receptor radioligands for positron emission tomography. Nuclear Medicine and Biology, 2017, 44, 69-77.	0.6	12
14	Imaging of Adenosine Receptors. , 2014, , 181-198.		2
15	Collisionâ€induced dissociation studies of caffeine in positive electrospray ionisation mass spectrometry using six deuterated isotopomers and one N1â€ethylated homologue. Rapid Communications in Mass Spectrometry, 2013, 27, 885-895.	1.5	16
16	Autoradiographic comparison of in vitro binding characteristics of various tritiated adenosine A2A receptor ligands in rat, mouse and pig brain and first ex vivo results. European Journal of Pharmacology, 2009, 616, 107-114.	3.5	16
17	Synthesis of the Main Metabolite in Human Blood of the A ₁ Adenosine Receptor Ligand [¹⁸ F]CPFPX. Organic Letters, 2009, 11, 4266-4269.	4.6	10
18	Metabolism of the A1 adenosine receptor PET ligand [18F]CPFPX by CYP1A2: implications for bolus/infusion PET studies. Nuclear Medicine and Biology, 2006, 33, 891-898.	0.6	27

#	Article	IF	CITATIONS
19	Synthesis andÂevaluation ofÂ7-amino-2-(2(3)-furyl)-5-phenylethylamino-oxazolo[5,4-d]pyrimidines asÂpotential A2A adenosine receptor antagonists forÂpositron emission tomography (PET). European Journal of Medicinal Chemistry, 2006, 41, 7-15.	5.5	33
20	METABOLISM OF THE A1 ADENOSINE RECEPTOR POSITRON EMISSION TOMOGRAPHY LIGAND [18F]8-CYCLOPENTYL-3-(3-FLUOROPROPYL)-1-PROPYLXANTHINE ([18F]CPFPX) IN RODENTS AND HUMANS. Drug Metabolism and Disposition, 2006, 34, 570-576.	3.3	28
21	Derivatives of 4,6-diamino-1,2-dihydro-2-phenyl-1,2,4-triazolo[4,3-a]quinoxalin-2H-1-one: potential antagonist ligands for imaging the A2A adenosine receptor by positron emission tomography (PET). European Journal of Medicinal Chemistry, 2005, 40, 421-437.	5.5	10
22	Quantification of cerebral A1 adenosine receptors in humans using [18F]CPFPX and PET: an equilibrium approach. NeuroImage, 2005, 24, 1192-1204.	4.2	25
23	Quantification of Cerebral A1 Adenosine Receptors in Humans using [18F]CPFPX and PET. Journal of Cerebral Blood Flow and Metabolism, 2004, 24, 323-333.	4.3	33
24	First no-carrier-added radioselenation of an adenosine-A1 receptor ligand. Journal of Labelled Compounds and Radiopharmaceuticals, 2004, 47, 415-427.	1.0	8
25	Binding of tritiated and radioiodinated ZM241,385 to brain A2A adenosine receptors. Nuclear Medicine and Biology, 2004, 31, 173-177.	0.6	14
26	In vivo imaging of rat brain A 1 adenosine receptor occupancy by caffeine. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 1440-1440.	6.4	10
27	Tritium-labelled 8-cyclopentyl-3-(3-fluoropropyl)-1-propylxanthine ([3H]CPFPX), a potent and selective antagonist for the A1adenosine receptor. Journal of Labelled Compounds and Radiopharmaceuticals, 2003, 46, 365-372.	1.0	10
28	Evaluation of radioiodinated 8-Cyclopentyl-3-[(E)-3-iodoprop-2-en-1-yl]-1-propylxanthine ([*I]CPIPX) as a new potential A1 adenosine receptor antagonist for SPECT. Nuclear Medicine and Biology, 2003, 30, 661-668.	0.6	5
29	Synthesis and Evaluation of No-Carrier-Added 8-Cyclopentyl-3-(3-[18F]fluoropropyl)-1-propylxanthine ([18F]CPFPX):Â A Potent and Selective A1-Adenosine Receptor Antagonist for in Vivo Imaging. Journal of Medicinal Chemistry, 2002, 45, 5150-5156.	6.4	76
30	Rapid Urinary lodide Test. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 1007-1012.	3.6	6
31	Radiochemical synthesis of [123I]2-iodo-lisuride for dopamine D2-receptor studies. Nuclear Medicine and Biology, 1996, 23, 373-376.	0.6	6
32	Recovery from wernicke's aphasia: A positron emission tomographic study. Annals of Neurology, 1995, 37, 723-732.	5.3	570
33	Distribution of photoassimilates in the pea plant: chronology of events in non-fertilized ovaries and effects of gibberellic acid. Planta, 1989, 180, 53-60.	3.2	34